Cue Biopharma Names Shao-Lee Lin as CEO; Advances Allergic Disease Program
Cue Biopharma names new CEO and advances allergic disease program with Phase 2 data expected in second half 2026.
Alvotech General Counsel Tanya Zharov Departs, Lisa Graver Named Successor
Alvotech General Counsel Tanya Zharov departs after six years; Lisa Graver named successor amid pipeline expansion and market commoditization.
Syndax Crosses $100M Quarterly Sales; Revuforj Transplant Rate Rises to 50%
Syndax reports Revuforj transplant rate rises to 50% in KMT2A patients, reshaping the commercial outlook for stem cell transplant...
Rhythm’s Setmelanotide Gains EU Approval for Hypothalamic Obesity
Setmelanotide gains EU approval for hypothalamic obesity, marking the first approved treatment for a rare condition affecting 10,000 patients...
Pacira Reports 5% Revenue Growth in Q1 2026 on EXPAREL Volume Gains
Pacira Reports 5% Revenue Growth in Q1 2026 on EXPAREL Volume Gains, with 7% increase in hospital and surgical...
Cue Biopharma Names Shao-Lee Lin as CEO to Lead Clinical-Stage Pivot
Cue Biopharma Names Shao-Lee Lin as CEO to lead clinical-stage pivot toward immune tolerance and allergy programs with 2H2026...
Alvotech General Counsel Tanya Zharov Steps Down After Six Years
Alvotech General Counsel Steps Down after six years, moving to board-level role at parent holding companies as company expands...
Syndax Surpasses $100M Quarterly Sales; Revumenib Transplant Rate Rises to 48%
Revumenib transplant rate climbs to 48% in R/R KMT2A patients, enabling maintenance therapy as second revenue event for Syndax.
Rhythm’s Setmelanotide Wins EU Approval for Acquired Hypothalamic Obesity
Rhythm's setmelanotide wins EU approval for acquired hypothalamic obesity, showing 19.8% placebo-adjusted BMI reduction at 52 weeks in the...
Pfizer’s Elrexfio Hits Phase 3 PFS Goal in Multiple Myeloma
Pfizer's Elrexfio hits Phase 3 PFS goal in multiple myeloma, delivering statistically significant progression-free survival data for the bispecific...